Autotransplantation for relapsed or refractory non-Hodgkin's lymphoma (NHL): Long-term follow-up and analysis of prognostic factors

A. P. Rapoport; R. Lifton; L. S. Constine; R. E. Duerst; C. N. Abboud; J. L. Liesveld; C. H. Packman; S. Eberly; R. F. Raubertas; B. A. Martin; W. R. Flesher; P. A. Kouides; J. F. Dipersio; J. M. Rowe

doi:10.1038/sj.bmt.1700772

Autotransplantation for relapsed or refractory non-Hodgkin's lymphoma (NHL): Long-term follow-up and analysis of prognostic factors

A. P. Rapoport^*, R. Lifton, L. S. Constine, R. E. Duerst, C. N. Abboud, J. L. Liesveld, C. H. Packman, S. Eberly, R. F. Raubertas, B. A. Martin, W. R. Flesher, P. A. Kouides, J. F. Dipersio, J. M. Rowe

^*Corresponding author for this work

Pediatrics

Research output: Contribution to journal › Article › peer-review

50 Scopus citations

Abstract

One hundred and thirty-six patients autografted for relapsed or refractory non-Hodgkin's lymphoma (NHL) were evaluated to assess long-term event-free survival and to identify important prognostic factors. High-dose therapy consisted primarily of carmustine (BCNU), etoposide, cytarabine, and cyclophosphamide (BEAC) followed by unpurged autologous stem cell rescue. The 5-year Kaplan-Meier event-free survival (EFS) for the entire cohort was 34% (95% confidence interval: 24-44%) with a median follow-up of approximately 3 years (range 0-7.5 years). For patients entering with minimal disease (defined as all areas ≤ 2 cm), the 5-year EFS was 40 vs 26% for those entering with bulky disease (P = 0.0004). In the multivariate analysis, minimal disease on entry and administration of involved-held XRT post-transplant were significantly associated with improved EFS; the latter association was observed mainly in the cohort of patients with bulky disease. The overall 100-day treatment-related mortality rate was 4.4% (3% for the last 71 patients). New strategies are needed to reduce the high rate of relapse (50-60%) following autotransplantation for relapsed or refractory NHL.

Original language	English (US)
Pages (from-to)	883-890
Number of pages	8
Journal	Bone Marrow Transplantation
Volume	19
Issue number	9
DOIs	https://doi.org/10.1038/sj.bmt.1700772
State	Published - May 1 1997

Funding

This work was supported in part by a Fellowship from the James P Wilmot Foundation (APR) and presented in part at the Annual Meeting of the American Society for Clinical Oncology, Philadelphia, May 19, 1996. We thank Kim Altobelli, Lynn Sievert, Sharon Swift, Wendy Silverman, Lucy Wedow and the dedicated nurses of the Samuel E Durand Bone Marrow Transplant Unit for the excellent care of these patients. Carol Weed and Barbara McIntyre provided expert secretarial assistance. We also thank Dr Marshall Lichtman for critically reviewing this manuscript.

Keywords

Autotransplantation
Lymphoma
Prognostic factors
Radiotherapy

ASJC Scopus subject areas

Transplantation
Hematology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/sj.bmt.1700772

Cite this

Rapoport, A. P., Lifton, R., Constine, L. S., Duerst, R. E., Abboud, C. N., Liesveld, J. L., Packman, C. H., Eberly, S., Raubertas, R. F., Martin, B. A., Flesher, W. R., Kouides, P. A., Dipersio, J. F., & Rowe, J. M. (1997). Autotransplantation for relapsed or refractory non-Hodgkin's lymphoma (NHL): Long-term follow-up and analysis of prognostic factors. Bone Marrow Transplantation, 19(9), 883-890. https://doi.org/10.1038/sj.bmt.1700772

@article{03bc4bf7f7614cfbb6e9787d97465c7a,

title = "Autotransplantation for relapsed or refractory non-Hodgkin's lymphoma (NHL): Long-term follow-up and analysis of prognostic factors",

abstract = "One hundred and thirty-six patients autografted for relapsed or refractory non-Hodgkin's lymphoma (NHL) were evaluated to assess long-term event-free survival and to identify important prognostic factors. High-dose therapy consisted primarily of carmustine (BCNU), etoposide, cytarabine, and cyclophosphamide (BEAC) followed by unpurged autologous stem cell rescue. The 5-year Kaplan-Meier event-free survival (EFS) for the entire cohort was 34% (95% confidence interval: 24-44%) with a median follow-up of approximately 3 years (range 0-7.5 years). For patients entering with minimal disease (defined as all areas ≤ 2 cm), the 5-year EFS was 40 vs 26% for those entering with bulky disease (P = 0.0004). In the multivariate analysis, minimal disease on entry and administration of involved-held XRT post-transplant were significantly associated with improved EFS; the latter association was observed mainly in the cohort of patients with bulky disease. The overall 100-day treatment-related mortality rate was 4.4% (3% for the last 71 patients). New strategies are needed to reduce the high rate of relapse (50-60%) following autotransplantation for relapsed or refractory NHL.",

keywords = "Autotransplantation, Lymphoma, Prognostic factors, Radiotherapy",

author = "Rapoport, {A. P.} and R. Lifton and Constine, {L. S.} and Duerst, {R. E.} and Abboud, {C. N.} and Liesveld, {J. L.} and Packman, {C. H.} and S. Eberly and Raubertas, {R. F.} and Martin, {B. A.} and Flesher, {W. R.} and Kouides, {P. A.} and Dipersio, {J. F.} and Rowe, {J. M.}",

note = "Funding Information: This work was supported in part by a Fellowship from the James P Wilmot Foundation (APR) and presented in part at the Annual Meeting of the American Society for Clinical Oncology, Philadelphia, May 19, 1996. We thank Kim Altobelli, Lynn Sievert, Sharon Swift, Wendy Silverman, Lucy Wedow and the dedicated nurses of the Samuel E Durand Bone Marrow Transplant Unit for the excellent care of these patients. Carol Weed and Barbara McIntyre provided expert secretarial assistance. We also thank Dr Marshall Lichtman for critically reviewing this manuscript.",

year = "1997",

month = may,

day = "1",

doi = "10.1038/sj.bmt.1700772",

language = "English (US)",

volume = "19",

pages = "883--890",

journal = "Bone Marrow Transplantation",

issn = "0268-3369",

publisher = "Springer Nature",

number = "9",

}

Rapoport, AP, Lifton, R, Constine, LS, Duerst, RE, Abboud, CN, Liesveld, JL, Packman, CH, Eberly, S, Raubertas, RF, Martin, BA, Flesher, WR, Kouides, PA, Dipersio, JF & Rowe, JM 1997, 'Autotransplantation for relapsed or refractory non-Hodgkin's lymphoma (NHL): Long-term follow-up and analysis of prognostic factors', Bone Marrow Transplantation, vol. 19, no. 9, pp. 883-890. https://doi.org/10.1038/sj.bmt.1700772

TY - JOUR

T1 - Autotransplantation for relapsed or refractory non-Hodgkin's lymphoma (NHL)

T2 - Long-term follow-up and analysis of prognostic factors

AU - Rapoport, A. P.

AU - Lifton, R.

AU - Constine, L. S.

AU - Duerst, R. E.

AU - Abboud, C. N.

AU - Liesveld, J. L.

AU - Packman, C. H.

AU - Eberly, S.

AU - Raubertas, R. F.

AU - Martin, B. A.

AU - Flesher, W. R.

AU - Kouides, P. A.

AU - Dipersio, J. F.

AU - Rowe, J. M.

N1 - Funding Information: This work was supported in part by a Fellowship from the James P Wilmot Foundation (APR) and presented in part at the Annual Meeting of the American Society for Clinical Oncology, Philadelphia, May 19, 1996. We thank Kim Altobelli, Lynn Sievert, Sharon Swift, Wendy Silverman, Lucy Wedow and the dedicated nurses of the Samuel E Durand Bone Marrow Transplant Unit for the excellent care of these patients. Carol Weed and Barbara McIntyre provided expert secretarial assistance. We also thank Dr Marshall Lichtman for critically reviewing this manuscript.

PY - 1997/5/1

Y1 - 1997/5/1

N2 - One hundred and thirty-six patients autografted for relapsed or refractory non-Hodgkin's lymphoma (NHL) were evaluated to assess long-term event-free survival and to identify important prognostic factors. High-dose therapy consisted primarily of carmustine (BCNU), etoposide, cytarabine, and cyclophosphamide (BEAC) followed by unpurged autologous stem cell rescue. The 5-year Kaplan-Meier event-free survival (EFS) for the entire cohort was 34% (95% confidence interval: 24-44%) with a median follow-up of approximately 3 years (range 0-7.5 years). For patients entering with minimal disease (defined as all areas ≤ 2 cm), the 5-year EFS was 40 vs 26% for those entering with bulky disease (P = 0.0004). In the multivariate analysis, minimal disease on entry and administration of involved-held XRT post-transplant were significantly associated with improved EFS; the latter association was observed mainly in the cohort of patients with bulky disease. The overall 100-day treatment-related mortality rate was 4.4% (3% for the last 71 patients). New strategies are needed to reduce the high rate of relapse (50-60%) following autotransplantation for relapsed or refractory NHL.

AB - One hundred and thirty-six patients autografted for relapsed or refractory non-Hodgkin's lymphoma (NHL) were evaluated to assess long-term event-free survival and to identify important prognostic factors. High-dose therapy consisted primarily of carmustine (BCNU), etoposide, cytarabine, and cyclophosphamide (BEAC) followed by unpurged autologous stem cell rescue. The 5-year Kaplan-Meier event-free survival (EFS) for the entire cohort was 34% (95% confidence interval: 24-44%) with a median follow-up of approximately 3 years (range 0-7.5 years). For patients entering with minimal disease (defined as all areas ≤ 2 cm), the 5-year EFS was 40 vs 26% for those entering with bulky disease (P = 0.0004). In the multivariate analysis, minimal disease on entry and administration of involved-held XRT post-transplant were significantly associated with improved EFS; the latter association was observed mainly in the cohort of patients with bulky disease. The overall 100-day treatment-related mortality rate was 4.4% (3% for the last 71 patients). New strategies are needed to reduce the high rate of relapse (50-60%) following autotransplantation for relapsed or refractory NHL.

KW - Autotransplantation

KW - Lymphoma

KW - Prognostic factors

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=17144438222&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17144438222&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1700772

DO - 10.1038/sj.bmt.1700772

M3 - Article

C2 - 9156261

AN - SCOPUS:17144438222

SN - 0268-3369

VL - 19

SP - 883

EP - 890

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

IS - 9

ER -

Autotransplantation for relapsed or refractory non-Hodgkin's lymphoma (NHL): Long-term follow-up and analysis of prognostic factors

Abstract

Funding

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this